Arch Therapeutics Inc (ARTH): Price and Financial Metrics


Arch Therapeutics Inc (ARTH): $0.12

0.00 (0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ARTH Stock Summary

  • ARTH has a higher market value than only 2.85% of US stocks; more precisely, its current market capitalization is $18,937,582.
  • ARTH's price/sales ratio is 1,893.76; that's higher than the P/S ratio of 99.51% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -11.48 for Arch Therapeutics Inc; that's greater than it is for only 1.54% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arch Therapeutics Inc are SILK, APDN, SNES, REFR, and PRLB.
  • Visit ARTH's SEC page to see the company's official filings. To visit the company's web site, go to www.archtherapeutics.com.

ARTH Valuation Summary

  • In comparison to the median Healthcare stock, ARTH's price/sales ratio is 57122.22% higher, now standing at 2060.
  • ARTH's price/earnings ratio has moved up 61.7 over the prior 100 months.
  • ARTH's price/earnings ratio has moved up 61.7 over the prior 100 months.

Below are key valuation metrics over time for ARTH.

Stock Date P/S P/B P/E EV/EBIT
ARTH 2021-08-06 2060 10.0 -3.9 -3.2
ARTH 2021-04-16 NA -8.3 -5.1 -5.3
ARTH 2018-08-09 NA 28.3 -10.4 -9.3
ARTH 2016-02-11 NA 12.4 -6.5 -6.5
ARTH 2015-10-05 NA -4.2 -21.2 -24.5
ARTH 2015-03-03 NA -2.5 -2.0 -2.0

ARTH Growth Metrics

  • Its 2 year net income to common stockholders growth rate is now at 20.67%.
  • Its year over year net income to common stockholders growth rate is now at -16.33%.
  • The 3 year price growth rate now stands at -22.68%.
ARTH's revenue has moved up $10,000 over the prior 67 months.

The table below shows ARTH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 0.01 -5.153099 -5.245139
2020-12-31 0 -4.853003 -4.185727
2020-09-30 0 -5.044755 -4.691377
2020-06-30 0 -4.971653 -4.12415
2020-03-31 0 -5.080859 -4.508945
2019-12-31 0 -5.267793 -3.607099

ARTH Stock Price Chart Interactive Chart >

Price chart for ARTH

ARTH Price/Volume Stats

Current price $0.12 52-week high $0.20
Prev. close $0.11 52-week low $0.06
Day low $0.09 Volume 138,914
Day high $0.12 Avg. volume 477,254
50-day MA $0.09 Dividend yield N/A
200-day MA $0.13 Market Cap 27.22M

Arch Therapeutics Inc (ARTH) Company Bio


Arch Therapeutics, Inc. operates as a life science medical device company. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. Its primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.


ARTH Latest News Stream


Event/Time News Detail
Loading, please wait...

ARTH Latest Social Stream


Loading social stream, please wait...

View Full ARTH Social Stream

Latest ARTH News From Around the Web

Below are the latest news stories about Arch Therapeutics Inc that investors may wish to consider to help them evaluate ARTH as an investment opportunity.

Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales

Medical Industry Veteran with Proven Track Record to Drive Commercialization Effort FRAMINGHAM, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that Dan Yrigoyen has joined the organization as Vice President of Sales. Mr. Yrigoyen will lead the Company’s national commercialization effort with a focus on revenue generation and channel development. Mr. Yr

Yahoo | July 12, 2021

Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021

FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcoming Ladenburg Thalmann 2021 Healthcare Conference, which shall be held July 13-14, 2021. Chief Executive Officer, Terry Norchi, MD, is scheduled to provide a corporate update and, along with Chief Financial Officer, Mike Abrams, participate in a subsequent quest

Yahoo | July 7, 2021

Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021. You m

Yahoo | June 2, 2021

Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer

Company Prepares for Next Stage of GrowthFRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021. In alignment with the Company’s succession plan, Mr. Abrams joins Arch’s financial team today, one week before assuming the role currently held by the Company’s Chief Financial Officer, Richard Davis. Mr. Davis will remain with the Company during a Transition Period, which will end on June 30, 2021, after which he will support the Company in a consulting role through December 31, 2021. Mr. Abrams has over 25 years of experience as a Chief Financial Officer...

Yahoo | May 3, 2021

Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021

Management to provide corporate update on Dermal Sciences and BioSurgeryFRAMINGHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), innovator of AC5® Advanced Wound System and other self-assembling Dermal Sciences and BioSurgery devices, announced today that it will be presenting at the H.C. Wainwright Global Life Sciences Conference, which will be held March 9-10, 2021. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Richard Davis, are scheduled to present via webcast and be available for meetings. The webcast will be available on-demand starting at 7:00 A.M. EST, Tuesday, March 9, 2021. You may access the live webcast by clicking here: webcast. Attendees may find conference information and registe...

Yahoo | March 2, 2021

Read More 'ARTH' Stories Here

ARTH Price Returns

1-mo 71.43%
3-mo 25.65%
6-mo -21.05%
1-year -31.82%
3-year -69.70%
5-year -80.57%
YTD -19.95%
2020 -39.94%
2019 -52.91%
2018 23.26%
2017 -26.31%
2016 188.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8031 seconds.